Using genetic testing to help personalize doses of warfarin therapy given to patients undergoing elective orthopedic surgery appears to lower the risk of combined adverse events compared with clinically guided dosing, according to research presented at the American College of Cardiology's 66th Annual Scientific Session.
↧